Anti-Static Polymer Compounds Market Size, Share & Trends Analysis Report By Formulation (Masterbatches, Pre-Compounded Anti-Static Compounds), By End Use (Electronics & Electricals, Packaging), By Region And Segment Forecasts, 2025 - 2033

Anti-hypertensive Drugs Market Summary

The global anti-hypertensive drugs market size was estimated at USD 24.88 billion in 2024 and is projected to reach USD 35.32 billion by 2033, growing at a CAGR of 3.96% from 2025 to 2033. The market is driven by the rising prevalence of hypertension due to aging populations, sedentary lifestyles, obesity, and urbanization.

Increasing awareness of cardiovascular health, advances in drug development, introduction of novel fixed-dose combinations, and improved diagnostics are boosting demand. Expanding healthcare infrastructure in emerging economies further supports market expansion.

High blood pressure (hypertension) increases the risk of heart disease and stroke, two major causes of death in the U.S. According to data published by the Centers for Disease Control and Prevention (CDC) in January 2025, High blood pressure affects nearly half of U.S. adults, causes over 664,000 deaths annually, and costs USD 131 billion each year. Prevalence is higher in men (50%) vs. women (44%), and highest among Black adults (58%), followed by Whites (49%), Asians (45%), and Hispanics (39%). Only 1 in 4 people with hypertension have it under control, with disparities across sex, race, and geography. Millions remain untreated, especially those with severely elevated blood pressure. The high prevalence of uncontrolled hypertension and low treatment adherence has driven strong demand for antihypertensive drugs. Rising costs of hypertension to the healthcare system further support investment in effective therapies, expanding the global anti-hypertensive drugs industry.

Recent regulatory approvals and positive clinical trial outcomes have accelerated market growth and reshaped therapeutic strategies. For instance, in June 2025, George Medicines received FDA approval for WIDAPLIK, the first and only single-pill triple combination therapy (telmisartan, amlodipine, indapamide) for hypertension in adults, including as an initial treatment. Available in three dosage strengths, WIDAPLIK offers the benefits of combination therapy in a simplified form, addressing the common need for multiple medications in hypertension management.

The U.S. commercial launch is expected in Q4 2025, with additional global regulatory submissions planned. The approval of WIDAPLIK marks a significant innovation in the anti-hypertensive drugs industry, introducing a convenient, first-in-class triple combination therapy for newly diagnosed and uncontrolled patients. By simplifying treatment and improving adherence, it is expected to capture strong demand in the US, where nearly half of adults have hypertension but only one in four has it under control. This approval strengthens the shift towards single-pill combinations and is likely to set new benchmarks for hypertension management globally.

Furthermore, in April 2024, Alnylam Pharmaceuticals announced positive results from the Phase 2 KARDIA-2 trial, evaluating zilebesiran, an investigational RNAi-based therapy targeting angiotensinogen (AGT) for uncontrolled hypertension. A single 600 mg subcutaneous dose added to standard antihypertensives (indapamide, amlodipine, or olmesartan) achieved significant reductions in ambulatory systolic BP of up to 12.1 mmHg at 3 months and sustained reductions up to 6 months.

Zilebesiran represents a first-in-class RNAi therapeutic in hypertension, offering a long-acting, twice-yearly dosing option that could disrupt the traditional oral drug market. By improving adherence and providing consistent BP control, it targets a major unmet need in patients with uncontrolled hypertension. Its success could significantly reshape the anti-hypertensive drugs industry, expanding precision and biologics-based approaches beyond conventional therapies.

Global Anti-hypertensive Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global anti-hypertensive drugs market report based on product, type, route of administration, distribution channel, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• ACE Inhibitors (ACEIs)
• Angiotensin II Receptor Blockers (ARBs)
• Direct Renin Inhibitor
• Calcium Channel Blockers
• Diuretics
• Mineralocorticoid Receptor Antagonists (MRAs)
• Beta-blockers
• Alpha-1 Blockers
• Central Alpha-2 Agonists
• Direct Vasodilators
• Fixed-dose Combinations (FDCs)
• Others
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Standard Hypertension
• Treatment-resistant Hypertension
• Hypertensive Emergency/ Urgency
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Transdermal
• Parenteral / Intravenous
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Retail Pharmacy
• Hospital Pharmacy
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 4-8 business days upon order notification. Show more